[Results] Meiji Holdings Co.,Ltd.: Pharmaceuticals operating profit up 39.6%, driven by growth in new drug products and AG contribution | The Yaku業 Daily — Comprehensive pharmaceutical industry news

The story

Meiji Holdings Co.,Ltd. announced its results for April–September 2026. Pharmaceuticals segment revenue was ¥124.8 billion, representing a 6.7% increase year on year.

According to the report, revenue growth was driven by growth in new drug products and a contribution from antibody-related AGS (AG), which had a positive impact on overall results.

Based on these results, the company indicated its policy of continuing growth in its pharmaceuticals business, and future developments are being closely watched.

At a glance

DateConsolidated results for April–September 2026

ScalePharmaceuticals segment revenue: ¥124.8 billion, up 6.7% year on year

NatureGrowth in new drug products and AG contribution

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

nk.jiho.jpNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.